Soluble PD-1 and PD-L1 as potential biomarkers for classical Hodgkin lymphoma

BLOCKADE OF THE PD-1 CHECKPOINT WITH ANTI-PD-L1 ANTIBODY AVELUMAB IS SUFFICIENT FOR CLINICAL ACTIVITY IN RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA (CHL)

(2017) R. Chen et al.   HEMATOLOGICAL ONCOLOGY

Soluble cytotoxic T-lymphocyte antigen 4: a favorable predictor in malignant tumors after therapy

(2017) Qiqi Liu et al.   OncoTargets and Therapy

Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer

(2017) Xinxin Zhu et al.   Oncotarget

The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints

(2016) S. Vardhana et al.   HAEMATOLOGICA

PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome

(2016) Margaretha G.M. Roemer et al.   JOURNAL OF CLINICAL ONCOLOGY

Current and future immunotherapeutic approaches in Hodgkin lymphoma

(2016) Paul J. Bröckelmann et al.   LEUKEMIA & LYMPHOMA

The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints

(2016) S. Vardhana et al.   HAEMATOLOGICA

Programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and EBV-encoded RNA (EBER) expression in Hodgkin lymphoma

(2015) Semra Paydas et al.   ANNALS OF HEMATOLOGY

Hodgkin Lymphoma: Diagnosis and Treatment

(2015) Stephen M. Ansell   MAYO CLINIC PROCEEDINGS

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

(2015) Stephen M. Ansell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Programmed death 1 expression in the peritumoral microenvironment is associated with a poorer prognosis in classical Hodgkin lymphoma

(2015) Young Wha Koh et al.   TUMOR BIOLOGY

High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial

(2014) D Rossille et al.   LEUKEMIA

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE